Unknown

Dataset Information

0

Evaluating genetic markers and neurobiochemical analytes for fluoxetine response using a panel of mouse inbred strains.


ABSTRACT:

Rationale

Identification of biomarkers that establish diagnosis or treatment response is critical to the advancement of research and management of patients with depression.

Objective

Our goal was to identify biomarkers that can potentially assess fluoxetine response and risk to poor treatment outcome.

Methods

We measured behavior, gene expression, and the levels of 36 neurobiochemical analytes across a panel of genetically diverse mouse inbred lines after chronic treatment with water or fluoxetine.

Results

Glyoxylase 1 (GLO1) and guanine nucleotide-binding protein 1 (GNB1) mostly account for baseline anxiety-like and depressive-like behavior, indicating a common biological link between depression and anxiety. Fluoxetine-induced biochemical alterations discriminated positive responders, while baseline neurobiochemical differences differentiated negative responders (p?ConclusionWe provided a comprehensive analysis of behavioral, neurobiochemical, and transcriptome data across 30 mouse inbred strains that has not been accomplished before. We identified biomarkers that influence fluoxetine response, which, altogether, implicate the importance of cellular genesis in fluoxetine treatment. More broadly, this approach can be used to assess a wide range of drug response phenotypes that are challenging to address in human samples.

SUBMITTER: Benton CS 

PROVIDER: S-EPMC3337404 | biostudies-literature | 2012 May

REPOSITORIES: biostudies-literature

altmetric image

Publications

Evaluating genetic markers and neurobiochemical analytes for fluoxetine response using a panel of mouse inbred strains.

Benton Cristina S CS   Miller Brooke H BH   Skwerer Sean S   Suzuki Oscar O   Schultz Laura E LE   Cameron Michael D MD   Marron J S JS   Pletcher Mathew T MT   Wiltshire Tim T  

Psychopharmacology 20111124 2


<h4>Rationale</h4>Identification of biomarkers that establish diagnosis or treatment response is critical to the advancement of research and management of patients with depression.<h4>Objective</h4>Our goal was to identify biomarkers that can potentially assess fluoxetine response and risk to poor treatment outcome.<h4>Methods</h4>We measured behavior, gene expression, and the levels of 36 neurobiochemical analytes across a panel of genetically diverse mouse inbred lines after chronic treatment  ...[more]

Similar Datasets

| S-EPMC3586763 | biostudies-literature
| S-EPMC4329520 | biostudies-other
| S-EPMC8741792 | biostudies-literature
2009-02-28 | GSE14563 | GEO
| S-EPMC3446305 | biostudies-literature
| S-EPMC2827351 | biostudies-literature
| S-EPMC516769 | biostudies-literature
| S-EPMC5874174 | biostudies-literature
| S-EPMC6543464 | biostudies-literature
| S-EPMC4201955 | biostudies-literature